Professor Naor is a busy man working tirelessly on the IP-protected peptide that has been developed thus far with grants from the University’s Yissum technology-transfer company, the Israeli government, Spherium Biomed of Spain and an Israeli pharmaceutical venture called Galmed.
Professor Naor has four disease targets in connection with 5-MER including Alzheimer’s, Crohn’s, multiple sclerosis and rheumatoid arthritis. All of these diseases share pathological amyloid proteins, which are targeted by the potential peptide drug developed by the Hebrew University of Jerusalem professor, reports ISRAEL21c.
Engaged, Interactive Professor Bombarded with Prospective Investor Requests
Naor has many readers and followers and someone sent him $5,000 donation he is using toward further research. He noted “The donor’s wife suffers from Alzheimer’s disease,” reports ISRAEL21c.
Several investors have communicated interest in investment opportunities associated with 5-MER.
Deal Gets Done: Yissum Brokers Deal with Israeli Biotech Venture
Yissum is a technology transfer company owned by the Hebrew University of Jerusalem. Founded in 1964, it is the third such company created in Israel. They identify and create breakthrough scientific research at Hebrew University, and they aspire to advance commercial solutions to the most pressing challenges of humanity.
Yissum structured a deal with Israel-based Galmed. The goal of the deal is to advance the peptide to human clinical studies (phase I) within 12 months and initiate a proof of concept phase 2 shortly thereafter.
David Naor likes to engage readers interested in his research efforts. He receives a lot of mail, mostly in relation to inquiries about diseases, such as Alzheimer’s disease. He has spent more than a decade researching a peptide of five amino acids (5-MER) that neutralizes the pathological amyloid proteins associated with some inflammatory and neurodegenerative diseases.Source: Israel21c